Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.

In the continuing study directed toward the development of peroxisome proliferator-activated receptor gamma (hPPARγ) agonist, we attempted to improve the water solubility of our previously developed hPPARγ-selective agonist 3, which is insufficiently soluble for practical use, by employing two strategies: introducing substituents to reduce its molecular planarity and decreasing its hydrophobicity via replacement of the adamantyl group with a heteroaromatic ring. The first approach proved ineffective, but the second was productive. Here, we report the design and synthesis of a series of α-benzyl phenylpropanoic acid-type hPPARγ partial agonists with improved aqueous solubility. Among them, we selected (R)-7j, which activates hPPARγ to the extent of about 65% of the maximum observed with a full agonist, for further evaluation. The ligand-binding mode and the reason for the partial-agonistic activity are discussed based on X-ray-determined structure of the complex of hPPARγ ligand-binding domain (LBD) and (R)-7j with previously reported ligand-LDB structures. Preliminal apoptotic effect of (R)-7j against human scirrhous gastric cancer cell line OCUM-2MD3 is also described.

[1]  M. Sakaguchi,et al.  Intraperitoneal administration of an adenovirus vector carrying REIC/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma. , 2011, Oncology reports.

[2]  M. Makishima,et al.  Design, synthesis, and evaluation of a novel series of α-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) α/δ dual agonists for the treatment of metabolic syndrome , 2006 .

[3]  Paulo C. T. Souza,et al.  GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain , 2012, The Journal of Biological Chemistry.

[4]  G. Landreth Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. , 2007, Current Alzheimer research.

[5]  I. Lu,et al.  Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.

[6]  E. Breslow,et al.  Effect of low pH on neurophysin-peptide interactions: implications for the stability of the amino-carboxylate salt bridge. , 1977, Biochemistry.

[7]  Shuichi Hirono,et al.  Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship. , 2011, Journal of medicinal chemistry.

[8]  E. Novellino,et al.  Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. , 2008, Journal of medicinal chemistry.

[9]  Naoyuki Kuwabara,et al.  Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype. , 2012, Journal of medicinal chemistry.

[10]  J. Schwabe,et al.  Molecular Determinants of the Balance between Co-repressor and Co-activator Recruitment to the Retinoic Acid Receptor* , 2003, Journal of Biological Chemistry.

[11]  R. Kaundal,et al.  Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. , 2010, Drug news & perspectives.

[12]  B. Testa,et al.  Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques , 2002, Cellular and Molecular Life Sciences CMLS.

[13]  Nanping Wang,et al.  Role of Peroxisome Proliferator-Activated Receptor-γ in Atherosclerosis , 2011 .

[14]  D. Dubé,et al.  REDUCTIVE N-ALKYLATION OF AMIDES, CARBAMATES AND UREAS , 1999 .

[15]  K. Mihara,et al.  Immortalization of normal human fibroblasts by treatment with 4‐nitroquinoline 1‐oxide , 1993, International journal of cancer.

[16]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[17]  S. Hirono,et al.  Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists. , 2011, Bioorganic & medicinal chemistry.

[18]  Dae Hwan Kim,et al.  Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. , 2009, World journal of gastroenterology.

[19]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[20]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[21]  S. Tsujitani,et al.  Recent results of therapy for scirrhous gastric cancer , 2009, Surgery Today.

[22]  J. Lehmann,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.

[23]  M. Makishima,et al.  SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail. , 2008, Bioorganic & medicinal chemistry letters.

[24]  E. Novellino,et al.  Insights into the Mechanism of Partial Agonism , 2007, Journal of Biological Chemistry.

[25]  Y. Matsuzawa,et al.  Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer Cells , 1999, Japanese journal of cancer research : Gann.

[26]  M. Makishima,et al.  Structure-Based Design and Synthesis of Fluorescent PPARα/δ Co-agonist and Its Application as a Probe for Fluorescent Polarization Assay of PPARδ Ligands , 2008 .

[27]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[28]  A. Ross,et al.  Malignant gastroenteric obstruction: therapeutic options. , 2007, Gastrointestinal endoscopy clinics of North America.

[29]  M. Makishima,et al.  Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists , 2007 .

[30]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.

[31]  M. Yashiro,et al.  Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice , 2004, Clinical & Experimental Metastasis.

[32]  K. Umesono,et al.  Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors , 1991, Cell.

[33]  J. Lehmann,et al.  A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Makishima,et al.  Improvement of water-solubility of biarylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) δ-selective partial agonists by disruption of molecular planarity/symmetry. , 2010, Bioorganic & medicinal chemistry.

[35]  Millard H. Lambert,et al.  Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .

[36]  B. Spiegelman,et al.  Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Mendez,et al.  PPAR&ggr; Inhibition of Cyclooxygenase-2, PGE2 Synthase, and Inducible Nitric Oxide Synthase in Cardiac Myocytes , 2003, Hypertension.

[38]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[39]  Hui Li,et al.  Role of Retinoid Receptor Coactivator Pockets in Cofactor Recruitment and Transcriptional Regulation* , 2001, The Journal of Biological Chemistry.

[40]  R. Morrison,et al.  Role of PPARγ in Regulating a Cascade Expression of Cyclin-dependent Kinase Inhibitors, p18(INK4c) and p21(Waf1/Cip1), during Adipogenesis* , 1999, The Journal of Biological Chemistry.

[41]  T. Okumura,et al.  Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells , 1999 .

[42]  K. Morikawa,et al.  The nuclear receptor PPARγ individually responds to serotonin‐ and fatty acid‐metabolites , 2010, The EMBO journal.

[43]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.

[44]  Y. Hashimoto,et al.  Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures , 2009, Acta crystallographica. Section D, Biological crystallography.